CCCC

C4 Therapeutics, Inc.

1.59 USD

Last updated Nov 30, 05:32 UTC

Yesterday HIGH

$1.6

Yesterday LOW

$1.45

52w HIGH

$9.41

52w LOW

$1.23

EPS

-0.55

PE

-2.89

Next Earnings

Feb 22, 2024

Overview News Insider Transactions Government Trades

C4 Therapeutics, Inc. stock is up 6.71% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. 67% of analysts rate it a buy.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting multiple myeloma and non-Hodgkin lymphomas. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

c4therapeutics.com

Lisa Levin

Wed Jul 5, 2023

Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.
Lisa Levin

Wed Jul 5, 2023

Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 50 points on Wednesday. The Dow traded down 0.17% to 34,361.31 while the NASDAQ fell 0.14% to 13,797.72. The S&P 500, also fell, dropping, 0.09% to 4,451.55.
Lisa Levin

Wed Jul 5, 2023

Dow Drops 150 Points; US Factory Orders Increase 0.3% In May

U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell 0.11% to 13,801.13. The S&P 500, also fell, dropping, 0.23% to 4,445.15.
Benzinga Insights

Wed Jul 5, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Adam Eckert

Wed Jul 5, 2023

C4 Therapeutics Stock Is Surging: What's Going On?

C4 Therapeutics Inc (NASDAQ: CCCC) shares are rising Wednesday after the clinical-stage biopharmaceutical company announced the FDA cleared its investigational new drug (IND)
Benzinga Newsdesk

Wed Jul 5, 2023

The FDA Clears C4 Therapeutics' Investigational New Drug Application For CFT8919 For Non-small Cell Lung Cancer; C4T Expects To Initiate Trials Outside Greater China After Betta Pharmaceuticals Concludes Phase 1 Dose Escalation Study In Greater China
Benzinga Insights

Tue May 30, 2023

The Latest Analyst Ratings for C4 Therapeutics
Benzinga Newsdesk

Tue May 30, 2023

C4 Therapeutics and Betta Pharmaceuticals Ink $392M Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC

C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how
Benzinga Newsdesk

Tue May 30, 2023

Evercore ISI Group Maintains Outperform on C4 Therapeutics, Lowers Price Target to $10

Evercore ISI Group analyst Gavin Clark-Gartner maintains C4 Therapeutics (NASDAQ:CCCC) with a Outperform and lowers the price target from $20 to $10.
Benzinga Insights

Thu May 18, 2023

Looking Into C4 Therapeutics's Return On Capital Employed

Morgan Stanley

Mon Nov 6, 07:50

hold

upgrade
BMO Capital

Fri Nov 3, 11:30

buy

confirm
HC Wainwright & Co.

Thu Nov 2, 07:03

buy

confirm